Cancer genome-sequencing studies have revealed a remarkably high prevalence of
mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes …

Small molecule-based targeting of chromatin regulatory factors has emerged as a promising
therapeutic strategy in recent years. The development and ongoing clinical evaluation of …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …

Most human epithelial tumors harbor numerous alterations, making it difficult to predict
which genes are required for tumor survival. To systematically identify cancer dependencies …

Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader'modules
found in proteins with varied functions, were highly tractable small-molecule targets. This is …

Although single-gene perturbation screens have revealed a number of new targets,
vulnerabilities specific to frequently altered drivers have not been uncovered. An important …

Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Elucidation of the mutational landscape of human cancer has progressed rapidly and been
accompanied by the development of therapeutics targeting mutant oncogenes. However, a …

The genomic landscape of breast cancer is complex, and inter-and intra-tumour
heterogeneity are important challenges in treating the disease. In this study, we sequence …

The genetic concept of synthetic lethality has now been validated clinically through the
demonstrated efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of …